Menu ×

HEALTHCARE & PHARMACEUTICAL

Bioengineered Protein Drug Market Segmentation By Drug Type; By Application; By Technology and By Drug Delivery Method (Traditional Methods and Novel Approaches) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Bioengineered Protein Drug Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • On January 4, 2017, Abbott acquired St. Jude Medical, Inc., a medical device firm. The acquisition is expected to help Abbott Laboratories expand its market share in medical devices and improve its bio-engineered stent product range worldwide.

  • On December 11, 2019, The World Health Organization (WHO), announced several changes to the treatment of drug-resistant tuberculosis (TB) and recommended the use of oral regimens containing Johnson & Johnson’s SIRTURO® (bedaquiline) for drug-resistant TB patients.

Introduction to Bioengineered Protein Drug

Protein plays a vital role in the growth and development of an individual. A protein molecule makes up a long chain of amino acids and controls all biological functions in the body, such as metabolic reactions, DNA replication, and other essential functions. Bioengineered proteins are designed to play a key role in all biological processes, to serve as effective therapeutic agents and to control a wide variety of functions including growth factors, hormones, vaccines, monoclonal antibodies, cytokines, and others. Owing to its versatility, effectiveness, bioreactivity and success rate in the treatment of life-threatening diseases, these special drugs are gaining interest among the manufacturers in the pharmaceutical industry.

Market Size and Forecast

The Centers for Disease Control and Prevention (CDC), in its statistical report “National Diabetes Statistics Report 2020”, stated that crude estimates for the prevalence of both diagnosed and undiagnosed diabetes amongst the US population aged 18 years or older in the year 2018 was registered to 34.1 million (10.5% of the US population).

Estimated Number of Adults Aged 18 Years

The prevalence of infectious diseases such as diabetes, cancer and others are primarily increasing the global demand for bioengineered protein drugs. As opposed to alternative treatments for cancer, diabetes, and other illnesses, bioengineered protein medications are more successful and often have minimal or no side effects. As a result, healthcare practitioners are increasingly prescribing medicines that are made up of bioengineered protein drugs. Moreover, with the escalating research and developments in bioengineered protein drugs and advancements in phase III clinical trials for the several medicines that are made from bioengineered protein drugs, are allowing pharmaceutical manufacturers to increasingly invest on the commercialization of this protein. CLICK TO DOWNLOAD SAMPLE REPORT

The bioengineered protein drug market is anticipated to record a notable CAGR during the forecast period, i.e. 2020-2028. The market is segmented by drug type into recombinant protein drug, vaccines, peptide hormones, therapeutic enzymes, monoclonal antibodies, replacement proteins, peptide antibiotics, cytokines, and blood products, out of which, the therapeutic enzymes segment is anticipated to hold the largest market share throughout the forecast period on account of the extensive use of therapeutic enzymes in the manufacturing of therapeutic proteins and in the processing of recombinant DNA. Macromolecular therapeutic proteins, such as, interferons, cytokines and monoclonal antibodies, are extensively used in the treatment of HIV, cancer, and other diseases.

Bioengineered Protein Drug Market Share

Growth Drivers

Technological Advancements in the Manufacturing of Bioengineered Protein Drugs to Drive the Market Growth

On account of the rapid technological advancements in the manufacturing of bioengineered protein drugs, immense developments in biopharmaceuticals and technological innovations in drug delivery systems, the bioengineered protein drug market is anticipated to grow remarkably over the forecast period. Over the years, the healthcare and pharmaceutical industry has observed a remarkable growth in the number of FDA approvals, especially in the development of bioengineered protein drugs. Consequently, the market players are raising their investments for the manufacturing of these drugs and further diversify their product portfolio, which is anticipated to drive the market growth.

Rise in the Prevalence of Chronic Diseases to Drive the Growth of the Market

According to the statistics of the World Health Organization (WHO), cancer is the second leading cause of death around the world. The statistics also stated that in the year 2018, cancer was responsible for an estimated 9.6 million deaths. In the other statistics by WHO, it stated that by 2030, the worldwide diabetes population will grow to 366 million.

The prevalence of chronic diseases, such as diabetes, cancer, and asthma among others, is growing at a steady pace globally. Owing to such a factor, healthcare practitioners are increasingly prescribing bioengineered protein drugs for the treatment of these diseases. Bioengineered protein drugs, which are also known as recombinant proteins, are widely used in the treatment of cancers and other chronic diseases, hormonal disorders, human injury, and others. These drugs are highly efficient and are designed to be target specific. As a result, these drugs are now-a-days one of the most widely preferred drugs. The players operating in the pharmaceutical and healthcare industry are progressively utilizing these drugs to manufacture medicines, which is anticipated to drive the market growth.

Restraints

High Cost of Treatment Associated with Bioengineered Protein Drugs

Treatment of diseases that require the use of bioengineered protein drugs usually cost high owing to the complications involved in the treatment process. As a result, the use of these drugs is not that feasible for countries belonging from the low- and middle-income nations. Such a factor is anticipated to affect the growth of the global bioengineered protein drug market.

Impact of COVID-19

During the initial re-opening phase of COVID-19 pandemic, several operators operating in the global bioengineered protein drug market had to face numerous challenges to balance their supply chain. With limited workforce, and stringent government norms, the players had to strategically lay out a plan to continue with their existing operations. Although, there was significantly a high demand for pharmaceutical products globally, yet many players couldn’t meet up to fulfil the required need, owing to the restrictions in trade across several nations.

Market Segmentation

Our in-depth analysis of the bioengineered protein drug market includes the following segments:

By Drug Type:

  • Recombinant Protein Drugs
  • Vaccines
    • Toxoid
    • Subunit/Conjugate
    • Inactivated/Killed Vaccines
    • Live Attenuated Vaccines
  • Peptide Hormones
    • Growth Hormones
    • Insulin
    • Erythropoietin
    • Luteinizing Hormones and Follicle Stimulating Hormones
  • Therapeutic Enzymes
    • Metabolic Enzymes
    • Digestive Enzymes
    • Other Enzymes
  • Monoclonal Antibodies
  • Replacement Proteins
  • Peptide Antibiotics
  • Cytokines
    • Interleukins
    • Interferons
    • Colony Stimulating Factors
  • Blood Products
    • C1 Esterase Inhibitor
    • Antithrombin
    • Thrombin
    • Immune Globulins
    • Coagulation Factors
    • Alpha 1-Protease Inhibitor

By Application:

  • Diabetes
  • Cancer
  • Skin Diseases
  • Heart Diseases
  • Blood Disorders
  • Neurodegenerative Diseases
  • Respiratory Diseases
  • Congenital Diseases
  • Infectious Diseases
  • Autoimmune Disorders
  • Arthritis
  • Others

By Technology:

  • Fractionation
  • Bioreactors & Microbial Cell Fermentation
  • Bioengineered Protein Drugs Produced by Transgenic Microorganisms, Plants & Animals
  • Genetic Engineering
  • Genetically Modified Organisms
  • Cell Culture
  • Pharming
  • Others

By Drug Delivery Method:

  • Traditional Methods
    • Oral
    • Topical
    • Transmucosal
    • Inhalation
    • Parenteral
  • Novel Approaches
    • Micelles
    • Microspheres
    • Microemulsions
    • Liposomes
    • Prodrug
    • Nanoparticles
    • Hydrogels
    • Thin-Film Drug Delivery

By Region

The bioengineered protein drug market is segmented based on region into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to register the largest market share throughout the forecast period, followed by the market in Europe. North America is known to have a strong network of drug companies. Backed by the increasing expenditure on healthcare, both by public and private entities, along with the increase in research and developmental activities and for the prevalence of chronic diseases amongst individuals in the region, the North America bioengineered protein drug market is anticipated to grow with a notable CAGR during the forecast period.

The bioengineered protein drug market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved